Immunovant (IMVT): Analyst Targets Suggest +27% Upside to $47

Key Takeaways

• The central stock price target of $47 is the arithmetic mean of seven individually verified, current analyst price targets reviewed for this analysis, rounded from an underlying mean of roughly $47.43.
• With shares near $37.04, reaching $47 would require a gain of about 27%, a substantial move for a clinical-stage biotechnology company.
• Individual analyst price targets span a wide range, from $33 (Truist) up to $62 (Citigroup), reflecting genuine disagreement about the lead drug candidate's prospects.
• The strongest support comes from positive Phase 2 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis and a $722.3 million cash position.
• The biggest risks are binary clinical outcomes, uncertainty about the path to registration, and a history of pipeline setbacks, including a discontinued cutaneous lupus program.
• For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for additional context and updates.
• You can also explore Trending AI Robots to see AI-driven strategies monitoring stocks and ETFs in changing market conditions.

Analyst Price Targets and Consensus View

Immunovant, Inc. (IMVT) is a clinical-stage immunology company developing IMVT-1402, an investigational FcRn (neonatal Fc receptor) inhibitor for autoimmune diseases. It is a subsidiary of Roivant Sciences and generates no product revenue, so its analyst price targets rest almost entirely on clinical data and the value of its pipeline.

For this analysis, seven current, individually attributed targets were reviewed. On November 10, 2026, Truist kept a Hold rating and raised its target to $33; H.C. Wainwright reiterated Buy at $41; Wells Fargo raised its target to $47 with an Overweight rating; and Bank of America Securities raised its target to $46 with a Buy rating. Earlier actions include J.P. Morgan's Overweight with a $50 target, LifeSci Capital's Buy at $53, and Citigroup's $62 target. The low-to-high range across these targets is $33 to $62, and their mean is about $47.43, rounded to a $47 central target. Aggregators report a broader "Buy" consensus, though the spread between the most cautious and most optimistic views is unusually wide, underscoring how much depends on upcoming clinical and regulatory outcomes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

Shares closed near $37.04 on November 11, 2026. Reaching $47 would require a rise of roughly 27%, a substantial move. The recent catalyst was a November 9 fiscal second-quarter update in which IMVT-1402 (600 mg) met the primary endpoint of a randomized-withdrawal trial in difficult-to-treat rheumatoid arthritis, with a 92.5% ACR20 response versus 75.6% for placebo. The company also reported a narrower-than-expected adjusted loss of $0.47 per share and held $722.3 million in cash, which it says funds operations to a potential commercial launch in Graves' disease. The path toward $47 likely depends on constructive FDA (Food and Drug Administration) discussions on the rheumatoid arthritis registrational program and further positive data readouts.

What Could Support a Move Toward the Target

• Clinically meaningful rheumatoid arthritis data that met its primary endpoint and showed deep, durable responses, including among patients who had failed JAK inhibitor therapy.
• A strong balance sheet providing multi-year cash runway and reducing near-term dilution risk.
• A favorable analyst posture: most covering firms rate the stock Buy or Overweight, and several raised targets following the data update.
• A broad pipeline, including ongoing work in Graves' disease and myasthenia gravis, offering multiple catalysts beyond a single indication.

What Could Prevent the Target From Being Reached

• Binary clinical risk: a disappointing Phase 3 or registrational result could reset the valuation sharply.
• Regulatory uncertainty, as the FDA path for the rheumatoid arthritis program is not yet established.
• Pipeline execution history, including the earlier deprioritization of batoclimab and a discontinued cutaneous lupus program.
• Cautious analyst views, such as Truist's Hold, which note that the responder-enriched trial design may not fully predict conventional Phase 3 success.

Technical Levels and Market Structure

The stock's 52-week range is roughly $21.86 to $45.42, meaning the $47 central target sits just above the prior 52-week high. That makes the $45 area a notable resistance level, while prior consolidation in the low-$30s and near $28–$30 represents nearby support. A sustained move toward $47 would likely require a confirmed breakout above the prior high rather than a short-lived gap on clinical headlines.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though firms vary in their assumptions. Key items to monitor include FDA feedback on the rheumatoid arthritis registrational design, expected 2027 data from IMVT-1402 in Graves' disease and myasthenia gravis, quarterly cash-burn and cash-runway updates, and any analyst target or rating revisions after clinical readouts. From what I see, tracking these milestones closely helps put the wide target range into perspective.

Using AI Daily Buy/Sell Signals for Broader Context

For traders seeking a more systematic view, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. This can help traders discover new opportunities, keep an eye on existing positions, and spot changing trends more efficiently than manual screening. Those looking to complement their own research with automated, data-driven alerts may find these signals a useful addition to their workflow. I find running AI Daily Buy/Sell Signals on names like this one gives me an extra layer of confirmation when clinical news hits.

Final Assessment

Whether Immunovant can reach $47 depends chiefly on translating a promising Phase 2 rheumatoid arthritis readout into a credible registration path and additional positive data. The $47 central target, derived from the average of verified analyst targets, sits roughly 27% above the current price and just above the 52-week high, making it a substantial but not extreme objective. Support comes from encouraging efficacy data, a strong cash position, and a broadly constructive analyst stance, while the principal obstacles are binary clinical risk, regulatory uncertainty, and a mixed pipeline track record. With targets ranging from $33 to $62, the wide dispersion reflects genuine uncertainty; investors should monitor FDA guidance and upcoming data readouts rather than treat the mean target as a forecast.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Harry Richardson|Expert

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume